NEXI (NexImmune) Days Sales Outstanding : 0.00 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NexImmune Days Sales Outstanding?

NexImmune's average Accounts Receivable for the three months ended in Jun. 2024 was $0.00 Mil. NexImmune's Revenue for the three months ended in Jun. 2024 was $0.00 Mil.

The historical rank and industry rank for NexImmune's Days Sales Outstanding or its related term are showing as below:

NEXI's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 70.705
* Ranked among companies with meaningful Days Sales Outstanding only.

NexImmune's Days Sales Outstanding stayed the same from Jun. 2023 (0.00) to Jun. 2024 (0.00).

NexImmune Days Sales Outstanding Historical Data

The historical data trend for NexImmune's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NexImmune Days Sales Outstanding Chart

NexImmune Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

NexImmune Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of NexImmune's Days Sales Outstanding

For the Biotechnology subindustry, NexImmune's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NexImmune's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NexImmune's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where NexImmune's Days Sales Outstanding falls into.

NexImmune Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

NexImmune's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

NexImmune's Days Sales Outstanding for the quarter that ended in Jun. 2024 is calculated as:

	Days Sales Outstanding (Q: Jun. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Mar. 2024 )	+	Accounts Receivable (A: Jun. 2024 ))	/	count )	/	Revenue (A: Jun. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

NexImmune (OTCPK:NEXI) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

NexImmune Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of NexImmune's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

NexImmune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NexImmune Inc (OTCPK:NEXI) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

9119 Gaither Road, Gaithersburg, MD, USA, 20877

Website

https://www.neximmune.com

NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.

Executives

Alan S. Roemer	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Timothy Stover	officer: VP, Corporate Controller	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Sol J Barer	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Zhengbin Yao	director	10301 STELLA LINK ROAD, HOUSTON TX 77025
Leena Gandhi	director	C/O NEXIMMUNE, 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Timothy Bertram	director	C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403
Paul D'angio	director	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Grant Verstandig	director	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Mathias Oelke	officer: Chief Science Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20878
Kristi Jones	officer: Chief Operating Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Jerome B Zeldis	officer: EVP of R&D	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Scott Carmer	director, officer: President and CEO	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
John Trainer	officer: Chief Financial Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877
Robert Douglas Knight	officer: Chief Medical Officer	C/O NEXIMMUNE, INC., 9119 GAITHER ROAD, GAITHERSBURG MD 20877